Table 3.
Open in new tab

Rates of Fistula Closure Adjusted for Abscess, Exposure to Immunomodulator and Time to Anti-TNF Comparing Patients With and Without an EUA

No EUAEUAAdjusted OR (95% CI)P Value
Fistula closure
 3 mo40/119 (33.6)15/65 (23.1)0.7 (0.3-1.8).50
 6 mo45/114 (39.5)20/66 (30.3)0.8 (0.4-2.0).70
 12 mo50/114 (43.9)24/63 (38.1)1.0 (0.4-2.2).92
No EUAEUAAdjusted OR (95% CI)P Value
Fistula closure
 3 mo40/119 (33.6)15/65 (23.1)0.7 (0.3-1.8).50
 6 mo45/114 (39.5)20/66 (30.3)0.8 (0.4-2.0).70
 12 mo50/114 (43.9)24/63 (38.1)1.0 (0.4-2.2).92

Values are n/n (%), unless otherwise indicated. Analysis adjusted for abscess, number of fistula tracts, concomitant immunomodulator, sex and time to anti-TNF start.

Abbreviations: CI, confidence interval; EUA, exam under anesthesia; OR, odds ratio; TNF, tumor necrosis factor.

Table 3.
Open in new tab

Rates of Fistula Closure Adjusted for Abscess, Exposure to Immunomodulator and Time to Anti-TNF Comparing Patients With and Without an EUA

No EUAEUAAdjusted OR (95% CI)P Value
Fistula closure
 3 mo40/119 (33.6)15/65 (23.1)0.7 (0.3-1.8).50
 6 mo45/114 (39.5)20/66 (30.3)0.8 (0.4-2.0).70
 12 mo50/114 (43.9)24/63 (38.1)1.0 (0.4-2.2).92
No EUAEUAAdjusted OR (95% CI)P Value
Fistula closure
 3 mo40/119 (33.6)15/65 (23.1)0.7 (0.3-1.8).50
 6 mo45/114 (39.5)20/66 (30.3)0.8 (0.4-2.0).70
 12 mo50/114 (43.9)24/63 (38.1)1.0 (0.4-2.2).92

Values are n/n (%), unless otherwise indicated. Analysis adjusted for abscess, number of fistula tracts, concomitant immunomodulator, sex and time to anti-TNF start.

Abbreviations: CI, confidence interval; EUA, exam under anesthesia; OR, odds ratio; TNF, tumor necrosis factor.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close